MFS
AVDL

MSI Financial Services’s Avadel Pharmaceuticals AVDL Stock Holding History

MSI Financial Services’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1
Closed – – 3949
2015
Q4 		$0 Hold
1
– – ﹤0.01% 3847
2015
Q3 		$0 Hold
1
– – ﹤0.01% 3161
2015
Q2 		$0 Hold
1
– – ﹤0.01% 3080
2015
Q1 		$0 Buy
+1
New +$16 ﹤0.01% 3011

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
FPC
Falcon Point Capital San Francisco, California $11.9M AUM 55.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

MSI Financial Services's AVDL Position: Q1 2016 in Review

MSI Financial Services sold out of Avadel Pharmaceuticals (AVDL) in Q1 2016, closing a stake of 1 share.

MSI Financial Services first reported a position in AVDL in Q1 2015 and held it in 4 quarters. The position peaked at $0 in Q4 2015. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2016.

  • MSI Financial Services reported no remaining Avadel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • MSI Financial Services sold 1 Avadel Pharmaceuticals share in Q1 2016.
  • MSI Financial Services first reported a position in Avadel Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • MSI Financial Services's Avadel Pharmaceuticals position peaked at $0 in Q4 2015.
  • 81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2016.

Based on MSI Financial Services's 13F filing for Q1 2016, filed 22 Apr 2016.